Bristol Myers Squibb's Iberdomide Shows Promise in Improving MRD Negativity in Multiple Myeloma
TL;DR Summary
Bristol Myers Squibb announced that their Phase 3 EXCALIBER-RRMM study showed that combining iberdomide with standard therapies significantly improved minimal residual disease negativity rates in relapsed or refractory multiple myeloma patients, with the trial continuing to evaluate other endpoints.
Topics:business#bristol-myers-squibb#clinical-trial#healthcare#iberdomide#mrd-negativity#multiple-myeloma
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
5 min
vs 6 min read
Condensed
96%
1,026 → 39 words
Want the full story? Read the original article
Read on Bristol Myers Squibb